The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial.
S. H. Boeck
Honoraria - Roche
Research Funding - Roche
A. Jung
No relevant relationships to disclose
R. P. Laubender
No relevant relationships to disclose
J. Neumann
No relevant relationships to disclose
R. Egg
No relevant relationships to disclose
C. Goritschan
No relevant relationships to disclose
U. Vehling-Kaiser
No relevant relationships to disclose
C. Winkelmann
No relevant relationships to disclose
L. Fischer von Weikersthal
No relevant relationships to disclose
M. R. Clemens
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
T. C. Gauler
Honoraria - Roche
A. Marten
No relevant relationships to disclose
S. Klein
No relevant relationships to disclose
G. Kojouharoff
No relevant relationships to disclose
M. Barner
No relevant relationships to disclose
M. Geissler
No relevant relationships to disclose
T. F. Greten
Honoraria - Roche
U. Mansmann
No relevant relationships to disclose
T. Kirchner
Stock Ownership - Roche
Honoraria - Roche
Research Funding - Roche
V. Heinemann
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche